BenchSci Partners with Google Cloud to Close Biology’s Infrastructure Gap

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire BenchSci Partners with Google Cloud to Close Biology's Infrastructure GapAuthor of the article:EMET, BenchSci’s agentic research environment, will run on Google Cloud as its primary infrastructure—establishing BenchSci as a key partner and provider of scientific reasoning and agentsTHIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountSolution combines BenchSci’s proprietary biological knowledge graph, closed-access data, ontologies, agents, and scientific reasoning with Google’s frontier life sciences AI models, AlphaGenome and AlphaFold 3, in a single environment for preclinical R&DTORONTO — BenchSci, a leading provider of AI software for biopharma research and development, today announced a strategic, multi-year initiative establishing Google Cloud as the primary infrastructure platform for EMET, BenchSci’s agentic research environment for preclinical drug discovery.The combined solution gives pharmaceutical scientists unified access to BenchSci’s proprietary biological knowledge graph—858 million nodes, 2.2 billion relationship edges, and legal access to 16 million closed-access scientific papers—alongside Google’s frontier life sciences AI models, including AlphaGenome and AlphaFold 3, within a single, purpose-built environment for preclinical R&D.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againof drugs fail in the clinic, not due to lack of data, but because that data has never converged. Scientists spendof their time manually stitching together paywalled literature, siloed databases, disconnected tools, and internal data locked in spreadsheets. While other technical disciplines solved this infrastructure challenge, biology has historically lacked a unified foundation.EMET addresses this gap by giving every scientist a series of agentic assistants—unifying data, models, software packages, workflows, and scientific reasoning into a single environment purpose-built for preclinical R&D. By running EMET on Google Cloud, BenchSci customers can now gain integrated access to the most advanced life sciences AI models available alongside BenchSci’s proprietary scientific foundation.The majority of the top 20 pharmaceutical companies by revenue are existing BenchSci customers. Across its customer base, 80% of users report 60% efficiency gains, with some research teams achieving up to 50x time savings on complex workflows, according to BenchSci data.“Every other technical discipline built a unified stack, and productivity exploded. Biology never did—until now,” said Liran Belenzon, CEO and co-founder of BenchSci. “Running on Google Cloud, with AlphaGenome and AlphaFold integrated natively alongside BenchSci’s knowledge graph, EMET gives scientists the complete picture of the biology before a drug ever enters the clinic. That’s how we close the 70% failure gap.”“At Google Cloud, we believe AI’s greatest purpose is accelerating discoveries that save lives, and that requires exactly the kind of unified scientific infrastructure BenchSci has built with EMET,” said Shweta Maniar, global director, Life Science Strategy & Solutions, Google Cloud. “BenchSci has built something the life sciences industry has been missing for decades: a true scientific foundation that makes sense of the data researchers have always had but could never fully use. By powering that foundation with Google Cloud technologies, we are turning biology’s biggest challenge into its biggest opportunity for patients.”BenchSci is working with Google Cloud to integrate EMET into the Google Cloud Marketplace, which will soon allow biopharma and other life science enterprises operating in Google Cloud environments to simplify access and billing.BenchSci is a world leader in AI software for biopharma research and development on a mission to exponentially increase the speed and quality of life-saving R&D to help bring new medicines to patients faster. We apply AI to understand how disease biology works throughout the drug discovery pipeline to solve the number one reason drug discovery projects fail—getting the biology wrong. EMET, BenchSci’s agentic AI workbench, unifies data, models, workflows, and scientific reasoning into a single environment purpose-built for preclinical R&D — giving every scientist an agentic team of PhD scientists to reason through disease biology behind every question. Backed by top-tier investors, including Generation Investment Management, iNovia Capital, TCV, F-Prime, Gradient Ventures (Google’s AI fund), and Golden Ventures, BenchSci has raised over $200 million. Our platform accelerates science at 16 top-20 pharmaceutical companies and over 4,500 leading research centers worldwide. For more information about BenchSci, visit www.benchsci.com.View source version on businesswire.com: Media Contact Information: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.